Harrow Health Inc (HROW) - Total Assets
Based on the latest financial reports, Harrow Health Inc (HROW) holds total assets worth $363.07 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Harrow Health Inc (HROW) shareholders funds for net asset value and shareholders' equity analysis.
Harrow Health Inc - Total Assets Trend (2005–2024)
This chart illustrates how Harrow Health Inc's total assets have evolved over time, based on quarterly financial data.
Harrow Health Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Harrow Health Inc's total assets of $363.07 Million consist of 48.8% current assets and 51.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.2% |
| Accounts Receivable | $116.60 Million | 30.0% |
| Inventory | $10.70 Million | 2.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $186.70 Million | 48.0% |
| Goodwill | $332.00K | 0.1% |
Asset Composition Trend (2005–2024)
This chart illustrates how Harrow Health Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HROW company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Harrow Health Inc's current assets represent 48.8% of total assets in 2024, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 12.2% of total assets in 2024, down from 100.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 48.0% of total assets.
Harrow Health Inc Competitors by Total Assets
Key competitors of Harrow Health Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥16.53 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.87 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
China | CN¥4.69 Billion |
Harrow Health Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.72 | 1.55 | 3.79 |
| Quick Ratio | 2.52 | 1.44 | 3.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $112.20 Million | $52.06 Million | $30.18 Million |
Harrow Health Inc - Advanced Valuation Insights
This section examines the relationship between Harrow Health Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 37.57 |
| Latest Market Cap to Assets Ratio | 2.94 |
| Asset Growth Rate (YoY) | 24.8% |
| Total Assets | $388.97 Million |
| Market Capitalization | $1.14 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Harrow Health Inc's assets at a significant premium (2.94x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Harrow Health Inc's assets grew by 24.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Harrow Health Inc (2005–2024)
The table below shows the annual total assets of Harrow Health Inc from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $388.97 Million | +24.77% |
| 2023-12-31 | $311.75 Million | +98.54% |
| 2022-12-31 | $157.02 Million | +59.69% |
| 2021-12-31 | $98.33 Million | +71.08% |
| 2020-12-31 | $57.47 Million | -2.73% |
| 2019-12-31 | $59.09 Million | +19.48% |
| 2018-12-31 | $49.45 Million | +106.76% |
| 2017-12-31 | $23.92 Million | -12.22% |
| 2016-12-31 | $27.25 Million | +92.82% |
| 2015-12-31 | $14.13 Million | +37.97% |
| 2014-12-31 | $10.24 Million | -35.02% |
| 2013-12-31 | $15.76 Million | +47.22% |
| 2012-12-31 | $10.71 Million | +6551.46% |
| 2011-12-31 | $160.96K | -54.31% |
| 2010-12-31 | $352.29K | -78.93% |
| 2009-12-31 | $1.67 Million | -68.66% |
| 2008-12-31 | $5.34 Million | +25.82% |
| 2007-12-31 | $4.24 Million | +16706.92% |
| 2006-12-31 | $25.23K | -36.83% |
| 2005-12-31 | $39.94K | -- |
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, … Read more